{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:28:01Z","timestamp":1761863281955},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":548,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/bjh.12780","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T09:46:58Z","timestamp":1393840018000},"page":"510-518","source":"Crossref","is-referenced-by-count":32,"title":["Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study"],"prefix":"10.1111","volume":"165","author":[{"given":"Michael","family":"Wang","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center; Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie L.","family":"Popplewell","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center; Duarte CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert H.","family":"Collins","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center; Dallas TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine; Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack University Medical Center; Hackensack NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"University of Michigan Comprehensive Cancer Center; Ann Arbor MI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine; St. Louis MO USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Mayo Clinic; Rochester MN USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lister","sequence":"additional","affiliation":[{"name":"Western Pennsylvania Cancer Institute; Pittsburgh PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Fanning","sequence":"additional","affiliation":[{"name":"Greenville Health System Cancer Institute; Greenville SC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center; Sacramento CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Thaddeus","family":"Beck","sequence":"additional","affiliation":[{"name":"Highlands Oncology Group; Fayetteville AR USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Kaya","sequence":"additional","affiliation":[{"name":"Cancer Care Northwest; Spokane WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Robeva","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation; Florham Park NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Fan","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation; Florham Park NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Klimovsky","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation; Florham Park NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wing","family":"Cheung","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation; Florham Park NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azzeddine","family":"Cherfi","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG; Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owen A.","family":"O'Connor","sequence":"additional","affiliation":[{"name":"Center for Lymphoid Malignancies; Department of Medicine; Columbia University Medical Center; New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,2]]},"reference":[{"key":"10.1111\/bjh.12780-BIB0001|bjh12780-cit-0001","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"10.1111\/bjh.12780-BIB0002|bjh12780-cit-0002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a multi-center phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncology"},{"key":"10.1111\/bjh.12780-BIB0003|bjh12780-cit-0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nature Reviews - Cancer"},{"key":"10.1111\/bjh.12780-BIB0004|bjh12780-cit-0004","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.hoc.2007.06.011","article-title":"The International Harmonization Project for response criteria in lymphoma clinical trials","volume":"21","author":"Cheson","year":"2007","journal-title":"Hematology and Oncology Clinics of North America"},{"key":"10.1111\/bjh.12780-BIB0005|bjh12780-cit-0005","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12780-BIB0006|bjh12780-cit-0006","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/13543784.2012.719871","article-title":"NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy","volume":"21","author":"Civallero","year":"2012","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1111\/bjh.12780-BIB0007|bjh12780-cit-0007","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1046\/j.1365-2141.1998.00684.x","article-title":"Bone marrow and peripheral blood involvement in mantle cell lymphoma","volume":"101","author":"Cohen","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12780-BIB0008|bjh12780-cit-0008","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal","year":"2008","journal-title":"Blood"},{"key":"10.1111\/bjh.12780-BIB0009|bjh12780-cit-0009","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Nicolantonio","year":"2010","journal-title":"Journal of Clinical Investigation"},{"key":"10.1111\/bjh.12780-BIB0010|bjh12780-cit-0010","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1111\/bjh.12780-BIB0011|bjh12780-cit-0011","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12780-BIB0012|bjh12780-cit-0012","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/CMAR.S7960","article-title":"Temsirolimus in the treatment of relapsed and\/or refractory mantle cell lymphoma","volume":"2","author":"Galimberti","year":"2010","journal-title":"Cancer Managagement and Research"},{"key":"10.1111\/bjh.12780-BIB0013|bjh12780-cit-0013","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Annals of Oncology"},{"key":"10.1111\/bjh.12780-BIB0014|bjh12780-cit-0014","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12780-BIB0015|bjh12780-cit-0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.leu.2404471","article-title":"Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma","volume":"21","author":"Haritunians","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/bjh.12780-BIB0016|bjh12780-cit-0016","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12780-BIB0017|bjh12780-cit-0017","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1182\/blood.V118.21.2697.2697","article-title":"Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report of an ongoing phase I\/II trial","volume":"118","author":"Hess","year":"2011","journal-title":"Blood"},{"key":"10.1111\/bjh.12780-BIB0018|bjh12780-cit-0018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1111\/bjh.12780-BIB0019|bjh12780-cit-0019","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2141.2008.07199.x","article-title":"Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis","volume":"142","author":"Katzenberger","year":"2008","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12780-BIB0020|bjh12780-cit-0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.leukres.2012.02.010","article-title":"The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells","volume":"36","author":"Kim","year":"2012","journal-title":"Leukemia Research"},{"key":"10.1111\/bjh.12780-BIB0021|bjh12780-cit-0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1053\/j.seminhematol.2011.03.010","article-title":"Is there a role for \u201cwatch and wait\u201d in patients with mantle cell lymphoma?","volume":"48","author":"Martin","year":"2011","journal-title":"Seminars in Hematology"},{"key":"10.1111\/bjh.12780-BIB0022|bjh12780-cit-0022","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/1078-0432.CCR-11-2123","article-title":"PIK3CA\/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors","volume":"18","author":"Meric-Bernstam","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12780-BIB0023|bjh12780-cit-0023","unstructured":"National Comprehensive Cancer Network, Inc NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas 2013 http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf"},{"key":"10.1111\/bjh.12780-BIB0024|bjh12780-cit-0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2141.2008.07466.x","article-title":"Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trial","volume":"145","author":"O'Connor","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12780-BIB0025|bjh12780-cit-0025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.2353\/ajpath.2006.051078","article-title":"Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma","volume":"169","author":"Peponi","year":"2006","journal-title":"American Journal of Pathology"},{"key":"10.1111\/bjh.12780-BIB0026|bjh12780-cit-0026","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2011","journal-title":"Blood"},{"key":"10.1111\/bjh.12780-BIB0027|bjh12780-cit-0027","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 36\/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"10.1111\/bjh.12780-BIB0028|bjh12780-cit-0028","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways","volume":"130","author":"Rizzatti","year":"2005","journal-title":"British Journal of Haematology"},{"key":"10.1111\/bjh.12780-BIB0029|bjh12780-cit-0029","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1111\/bjh.12780-BIB0030|bjh12780-cit-0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1111\/bjh.12780-BIB0031|bjh12780-cit-0031","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.1158\/1078-0432.CCR-12-0351","article-title":"Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma","volume":"18","author":"Rosich","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1111\/bjh.12780-BIB0032|bjh12780-cit-0032","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"10.1111\/bjh.12780-BIB0033|bjh12780-cit-0033","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11912-011-0187-7","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategies","volume":"13","author":"Schatz","year":"2011","journal-title":"Current Oncology Reports"},{"key":"10.1111\/bjh.12780-BIB0034|bjh12780-cit-0034","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1038\/onc.2011.42","article-title":"PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs","volume":"2011","author":"Weigelt","year":"2011","journal-title":"Oncogene"},{"key":"10.1111\/bjh.12780-BIB0035|bjh12780-cit-0035","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"2005","author":"Witzig","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1111\/bjh.12780-BIB0036|bjh12780-cit-0036","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12780","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjh.12780\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T07:49:58Z","timestamp":1625384998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,2]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1111\/bjh.12780","relation":{},"ISSN":["0007-1048"],"issn-type":[{"value":"0007-1048","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3,2]]}}}